- Home
- Companies
- Alucent Biomedical Inc.
- Products
- Alucent - Speed AVF Maturation ...
Alucent - Speed AVF Maturation Technology for Dialysis Patients
Dialysis is a life-saving treatment for patients with end-stage renal disease. Creation of arteriovenous (AV) fistulas are often the best option for permanent vascular access in these patients. Once mature, AV fistulas allow a conduit for regular dialysis, however, failure rates remain high (reaching up to 70%) due to lack of fistula maturation; often requiring secondary surgeries or percutaneous interventions to promote clinical usability.
Alucent aims to improve AV fistula maturation by adding its NVS technology to the AVF procedure – with a particular focus on improving outcomes in the most challenging patients, those with veins with sub optimal diameters.
Pre-Clinical signals demonstrate NVS can potentially promote vein remodeling thus speeding & enhancing the physiological and functional maturation of the AVF – helping patients more rapidly and reliably have regular life-saving dialysis.